Natco Pharma Limited has announced that its board of directors has approved to acquire additional shareholding in Adcock Ingram Holdings Proprietary Limited subject to customary closing conditions and statutory compliances. This acquisition valued at Rs. 1,069 crore at the prevailing exchange rate will take Natco’s shareholding in Adcock Ingram from 35.75% to 49%.
Adcock Ingram has delivered a topline of US$ 423 million with an EBITDA of ~US$ 59 million for the period ending 9 months on March 31, 2026. Post transaction, Natco will be recognising 49% of profit after tax of Adcock Ingram in its books.
Adcock Ingram is a South African pharmaceutical company established in 1890 and ranked 2nd in the private and public pharmaceutical market in South Africa. The company manufactures, markets, and distributes healthcare products to both the private and public sectors of the market. Its portfolio includes an extensive range of prescription, over-the-counter (OTC), consumer and hospital products, manufactured in three facilities in South Africa and two in India. |